| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rosin targets the MAPK/ERK pathway. The MAPK/ERK pathway is a signaling cascade involved in cell proliferation, differentiation, and survival. By modulating this pathway, Rosin may exert its anti-inflammatory and neuroprotective effects. The compound's anti-inflammatory activity is attributed to its ability to inhibit pro-inflammatory signaling pathways. Its neuroprotective effects may involve the modulation of oxidative stress and inflammation in the central nervous system.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Rosin has antibacterial activity. The compound inhibits bacterial growth, though the specific spectrum of activity and mechanisms are not fully detailed. Rosin's anti-inflammatory activity has been demonstrated in cell-based assays, where it reduces the production of pro-inflammatory cytokines. Its neuroprotective effects have been studied in models of neurodegenerative disease, where it may protect neurons from oxidative stress and inflammation.
|
| ln Vivo |
In vivo activity of Rosin has not been extensively characterized in the available literature. As a natural product with potential therapeutic applications for inflammation and neurodegenerative diseases, Rosin may have efficacy in animal models of these conditions. However, detailed in vivo efficacy data, including specific disease models and dosing regimens, are not extensively reported. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Rosin are not well-characterized. As a natural product with activity against the MAPK/ERK pathway, Rosin's mechanism may involve modulation of kinase activity. Standard kinase assays using purified enzymes and peptide substrates could be employed to measure its effects on MAPK/ERK signaling. Anti-inflammatory activity may be assessed by measuring the inhibition of pro-inflammatory cytokine production in stimulated immune cells.
|
| Cell Assay |
Cellular assays for Rosin are conducted to evaluate its anti-inflammatory and neuroprotective activities. Immune cells (e.g., macrophages) are treated with the compound and stimulated with LPS or other inflammatory stimuli. Cytokine production (e.g., TNF-alpha, IL-6) is measured by ELISA. For neuroprotective studies, neuronal cells are treated with the compound and exposed to oxidative stress or other insults, and cell viability is assessed using MTT or similar assays. The compound's effects on MAPK/ERK signaling are assessed by Western blotting for phosphorylated ERK.
|
| Animal Protocol |
In vivo animal studies for Rosin are limited. For anti-inflammatory studies, animal models of inflammation (e.g., carrageenan-induced paw edema) could be used. For neuroprotective studies, models of neurodegenerative disease (e.g., MPTP-induced Parkinson's disease) could be employed. Animals would be treated with the compound via oral or intraperitoneal administration at various doses. Inflammatory markers or neurobehavioral outcomes would be assessed. However, specific in vivo study protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Rosin have not been extensively characterized. The compound has a molecular weight of 296.32 and a molecular formula of C1₅H20O₆. The compound is a natural product with moderate lipophilicity. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported in the available literature. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Rosin are limited. The compound may cause allergic contact dermatitis, particularly in cosmetic applications such as eyeshadow and mascara. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for activity studies. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Rosin is a solid resin extracted from pine trees and other plants (primarily coniferous trees). It is produced by heating fresh, liquid resin, causing its volatile liquid terpenoid components to vaporize. Rosin has applications in various commercial and industrial sectors, including printing, the lead and tin industry, and food production. In the pharmaceutical field, rosin is used for film formation and coating of tablets, as well as the preparation of enteric-coated formulations, and also for the formation of microcapsules and nanoparticles. Rosin has been shown to have antibacterial activity against Gram-positive bacteria. Rosin has been reported to be found in Rhodiola crenulata, Rhodiola sachalinensis, and several other organisms with relevant data. See also: Rosin (note moved to).
Rosin is a natural product with potential therapeutic applications for inflammation and neurodegenerative diseases. It targets the MAPK/ERK pathway and has antibacterial activity. The compound is a natural resin obtained from pine trees. It may cause allergic contact dermatitis. Rosin is not an FDA-approved drug and has no clinical indications. It is available in high purity (≥98%) and is typically stored at -20degC. |
| Molecular Formula |
C15H20O6
|
|---|---|
| Molecular Weight |
296.3157
|
| Exact Mass |
296.125
|
| Elemental Analysis |
C, 60.80; H, 6.80; O, 32.40
|
| CAS # |
85026-55-7
|
| PubChem CID |
5280656
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
542.4±50.0 °C at 760 mmHg
|
| Melting Point |
75-81ºC
|
| Flash Point |
281.8±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
-0.31
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
328
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C/C=C/C1C=CC=CC=1
|
| InChi Key |
KHPCPRHQVVSZAH-GUNCLKARSA-N
|
| InChi Code |
InChI=1S/C15H20O6/c16-9-11-12(17)13(18)14(19)15(21-11)20-8-4-7-10-5-2-1-3-6-10/h1-7,11-19H,8-9H2/b7-4+/t11-,12-,13+,14-,15-/m1/s1
|
| Chemical Name |
(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(E)-3-phenylprop-2-enoxy]oxane-3,4,5-triol
|
| Synonyms |
Rosin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~337.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3747 mL | 16.8737 mL | 33.7473 mL | |
| 5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | |
| 10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
